Abstracts

EVOLUTIONARY HISTORY OF HEPATITIS B VIRUS SUB-GENOTYPE D3 IN BOTSWANA

Background: Botswana has an intermediate Hepatitis B virus (HBV) prevalence of 2–7%. To date, three HBV genotypes (A, D and E) have been reported in Botswana at the prevalence rates 80%, 18.6%, and 1.4%, respectively. However, the evolutionary history of all the identified genotypes within the population of Botswana remains unexplored. Such evolutionary analysis of…

EARLY VIROLOGICAL OUTCOME OF DTG-BASED REGIMEN IN ADULT ARV-NAIVE PLHIV IN RWANDA

Background: In 2018, the Rwanda introduced DTG in the national HIV treatment guideline as the first-line regimen option for newly diagnosed HIV+ patients. The efficacy of DTG in the antiretroviral therapy (ART)‐naïve population has been widely demonstrated in randomized clinical trials, showing superiority compared to both non‐nucleoside reverse transcriptase inhibitors and protease inhibitors‐based regimens. The…

STUDY OF CHARACTERISTICS AND OUTCOMES OF KSHV INFLAMMATORY CYTOKINE SYNDROME (KICS)

Background: KSHV inflammatory cytokine syndrome (KICS), caused by Kaposi sarcoma herpesvirus (KSHV), is characterized by severe inflammatory signs (elevated C-reactive protein, elevated KSHV viral load) and symptoms without evidence of multicentric Castleman disease (MCD). KICS, predominantly occurs among people with HIV (PWH) and Kaposi sarcoma (KS), and has overlapping clinical features of MCD and primary…

EFFECT OF BNT162B2 ANTIGEN DOSAGE ON PROTECTION AGAINST SARS-CoV-2 OMICRON INFECTION

Background: Coronavirus Disease 2019 (COVID-19) vaccine antigen dosage may affect protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, but direct evidence to quantify this effect is lacking. Methods: A matched, retrospective, cohort study that emulated a randomized control trial was conducted in Qatar between February 3, 2022 and November 8, 2022, to provide…